Core Insights - The beauty industry in China is experiencing a significant performance divergence among leading companies, with a notable emphasis on quality improvement amidst a deep industry adjustment [1][2]. Group 1: Industry Performance - In the first half of 2025, retail sales of cosmetics in China increased by 2.9% year-on-year, with domestic brands capturing over 55% market share [2]. - Exports of cosmetics surged by 12% to 25.8 billion yuan, indicating strong overseas growth potential [2]. Group 2: Leading Companies - Leading companies like Proya, Mao Geping, and Shangmei continue to excel, while others like Huaxi Biological and Fulejia are lagging behind [2]. - Proya reported revenue of 5.362 billion yuan, a 7.21% increase, and a net profit of 799 million yuan, up 13.8% [4]. - Mao Geping achieved a revenue of 2.588 billion yuan, with a remarkable growth rate of 31.3%, and a net profit of 670 million yuan, reflecting a 36.1% increase [5]. - Shangmei's revenue reached 4.108 billion yuan, growing by 17.3%, with a net profit of 556 million yuan, up 34.7% [5]. - Juzhi Biological reported revenue of 3.113 billion yuan, a 22.5% increase, and a net profit of 1.182 billion yuan, up 20.2% [5]. Group 3: Underperforming Companies - Huaxi Biological reported a significant decline, with revenue dropping nearly 19.57% to 2.261 billion yuan and net profit falling 35.38% to 221 million yuan [6]. - Fulejia's revenue decreased by 8.15% to 863 million yuan, with a net profit decline of 32.54% to 230 million yuan, largely due to increased marketing expenses [9][11]. Group 4: Second-Tier Companies - Second-tier companies like Shanghai Jahwa, Marubi, and Shuiyang are showing improved performance [13]. - Shanghai Jahwa's revenue was 3.478 billion yuan, up 4.8%, with a net profit of 270 million yuan, increasing by 11.7% [14]. - Marubi achieved revenue of 1.769 billion yuan, a 30.83% increase, but net profit growth was only 5.21% [14]. - Shuiyang reported revenue of 2.5 billion yuan, a 9.02% increase, and a net profit of 123 million yuan, up 16.54% [14].

Core Viewpoint - The beauty industry in China is experiencing a significant performance divergence among leading companies, with a notable increase in quality, as evidenced by the half-year reports of domestic beauty brands [2]. Group 1: Leading Companies Performance - Leading beauty companies such as Proya, Mao Geping, and Shangmei continue to outperform, while Huaxi Biological and Fulejia are lagging behind [2][4]. - Proya reported a revenue of 5.362 billion yuan, a year-on-year increase of 7.21%, and a net profit of 799 million yuan, up 13.8%. However, its main brand experienced a slight revenue decline of 0.08% [5][6]. - Mao Geping, known as the "first stock of high-end domestic beauty," achieved a revenue of 2.588 billion yuan, with a net profit of 670 million yuan, both showing over 30% growth. The gross margin reached 84.2% [6]. - Shangmei's revenue was 4.108 billion yuan, growing 17.3%, with a net profit of 556 million yuan, up 34.7%. The "newpage" brand saw a revenue increase of 146.5% [6][7]. - Juzhi Biological reported a revenue of 3.113 billion yuan, a 22.5% increase, and a net profit of 1.182 billion yuan, up 20.2%, although growth rates have slowed compared to the previous year [7]. Group 2: Underperforming Companies - Huaxi Biological, referred to as the "first stock of hyaluronic acid," reported a revenue decline of 19.57% to 2.261 billion yuan and a net profit drop of 35.38% to 221 million yuan, marking its worst interim report since listing [9]. - The decline in Huaxi's revenue is attributed to a significant drop in its functional skincare business, which saw a 31.62% year-on-year decrease in 2024 [9]. - Fulejia's revenue was 863 million yuan, down 8.15%, with a net profit of 230 million yuan, a decrease of 32.54%. The company faced a substantial increase in sales expenses, which rose by 39.56% [11][12]. Group 3: Second-Tier Companies - Second-tier beauty companies such as Shanghai Jahwa, Marubi, and Shuiyang are showing improved performance [13][14]. - Shanghai Jahwa achieved a revenue of 3.478 billion yuan, a 4.75% increase, and a net profit of 266 million yuan, up 11.66%, attributed to online channel growth [15]. - Marubi reported a revenue of 1.769 billion yuan, a 30.83% increase, but its net profit only grew by 5.21%, indicating a potential profitability challenge [15][16]. - Shuiyang's revenue reached 2.5 billion yuan, a 9.02% increase, with a net profit of 123 million yuan, up 16.54%. The company is transitioning to a global high-end beauty brand management model [16].

Core Viewpoint - The company reported strong revenue and profit growth in the first half of 2025, driven by the performance of its brands and online sales channels [1][4]. Financial Performance - In 1H2025, the company achieved revenue of 3.11 billion yuan, a year-on-year increase of 22.5% [1] - The net profit attributable to shareholders was 1.18 billion yuan, up 20.2% year-on-year [1] - Adjusted net profit reached 1.21 billion yuan, reflecting a 17.4% increase compared to the previous year [1] Product Performance - The company's professional skincare products generated revenue of 3.10 billion yuan, with a growth rate of 22.5% [1] - Efficacy skincare products accounted for 2.41 billion yuan in revenue, growing by 24.2% and representing 77.4% of total revenue [1] - The medical dressings segment generated 690 million yuan, with a year-on-year growth of 17.1% [1] - The company's brands, 可复美 and 可丽金, reported revenues of 2.54 billion yuan and 500 million yuan, respectively, with growth rates of 22.7% and 26.9% [1][2] Sales Channels - Direct-to-consumer (DTC) online sales reached 1.82 billion yuan, up 13.3% year-on-year [2] - E-commerce platform sales surged to 390 million yuan, a significant increase of 133.6% [2] - Offline direct sales grew to 120 million yuan, reflecting a 74.3% increase [2] - The company has expanded its offline presence with 24 brand stores across various cities by the end of 1H2025 [3] Market Expansion - 可复美 has entered the Southeast Asian market by partnering with Watsons in Malaysia [3] - The company continues to enhance its online multi-platform strategy and refine operations, benefiting from the rapid expansion of beauty categories on platforms like JD.com [3] Profitability and Cost Management - The company's gross margin slightly decreased by 0.7 percentage points to 81.7%, attributed to changes in product mix and a decline in the proportion of high-margin medical dressing revenue [3] - Sales, management, and R&D expense ratios were 34.0%, 2.7%, and 1.3%, respectively, with a decrease in sales expense ratio due to a higher proportion of low-cost channels [3] Future Outlook - The company anticipates accelerated growth in the second half of the year, driven by increased brand marketing efforts and the potential approval of new medical aesthetic products [4] - The adjusted net profit forecasts for 2025-2027 are 2.59 billion, 3.45 billion, and 4.48 billion yuan, respectively [4]

Core Viewpoint - The company's 1H25 performance met expectations, with revenue of 3.11 billion yuan, a year-on-year increase of 22.5%, and a net profit attributable to shareholders of 1.18 billion yuan, up 20.2% year-on-year [1][2] Financial Performance - Revenue for 1H25 reached 3.11 billion yuan, reflecting a 22.5% year-on-year growth - Net profit attributable to shareholders was 1.18 billion yuan, representing a 20.2% increase year-on-year - Adjusted net profit stood at 1.21 billion yuan, with a year-on-year growth of 17.4% [1] Product Development and Market Trends - The product matrix continues to expand, driving rapid revenue growth for key brands: - Revenue for Kefu Mei was 2.54 billion yuan, up 22.7% year-on-year - Keli Jin generated 500 million yuan, with a year-on-year increase of 26.9% - Performance of key products includes: - Kefu Mei's collagen stick ranked first in Tmall's liquid essence sales during the 618 shopping festival - Keli Jin's upgraded collagen mask performed well [1][2] Profitability and Cost Management - Gross margin slightly declined by 0.7 percentage points to 81.7% due to changes in product mix - Sales expense ratio decreased by 1.1 percentage points to 35.1%, attributed to improved operational efficiency across online platforms - Net profit margin decreased by 0.7 percentage points to 38.0%, maintaining industry-leading profitability [2] Future Outlook - Short-term impacts from previous events are gradually dissipating, with clear marketing and promotional plans for the second half of the year - The company is expected to see further operational improvements in its cosmetics business and steady progress in its medical aesthetics pipeline [2] Earnings Forecast and Valuation - The profit forecast for 2025-2026 is maintained at 2.5 billion and 3.2 billion yuan respectively - Current stock price corresponds to a 20x and 16x P/E for 2025 and 2026, with a target price of 82 HKD, indicating a 57% upside potential [3]

Core Viewpoint - The company is experiencing steady growth in H1 2025, with a focus on collagen products and a strong performance in the skincare segment, supported by dual-brand strategies and effective channel expansion [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 3.113 billion yuan, representing a year-on-year increase of 22.5%, and a net profit attributable to shareholders of 1.182 billion yuan, up 20.2% [1]. - The company's gross margin for H1 2025 was 81.7%, a slight decrease of 0.7 percentage points, influenced by product mix adjustments [2]. Product and Brand Development - The company has a robust product matrix, with the "可复美" brand generating revenue of 2.542 billion yuan (up 22.7%) and the "可丽金" brand achieving 503 million yuan (up 26.9%) in H1 2025 [2]. - The product lineup includes a series of medical devices and five skincare efficacy series, with notable performance from collagen dressings and upgraded star products [2]. Channel Expansion - The company has expanded its offline presence to approximately 1,700 public hospitals and 3,000 private hospitals and clinics, while also increasing its brand-specific stores to 24 in cities like Hangzhou, Nanjing, and Tianjin [2]. - Online sales through direct-to-consumer (DTC) stores and e-commerce platforms saw significant growth, with e-commerce revenue increasing by 133.6% [2]. Research and Development - In H1 2025, the company filed for 19 new patents and had two medical devices related to recombinant collagen approved for review, indicating a strong focus on innovation in the medical aesthetics sector [2].

Core Viewpoint - The company is experiencing steady growth in revenue and net profit, with a focus on cost control and the performance of key products and new launches [1][2]. Group 1: Financial Performance - In H1 2025, the company reported revenue of 31.13 billion RMB, a year-on-year increase of 22.5%, and a net profit attributable to shareholders of 11.82 billion RMB, up 20.2% [1]. - The adjusted net profit for H1 2025 was 12.05 billion RMB, reflecting a 17.4% year-on-year growth [1]. - The gross margin for H1 2025 was 81.7%, a decrease of 0.7 percentage points year-on-year, primarily due to changes in product mix and an increase in the proportion of skincare products [1]. Group 2: Cost Management - The company has effectively controlled expenses, with sales expense ratio, management expense ratio, and R&D expense ratio at 34%, 2.7%, and 1.3% respectively, showing a decrease of 1.1, an increase of 0.1, and a decrease of 0.6 percentage points year-on-year [1]. - The net profit margin for H1 2025 was 38%, down 0.6 percentage points year-on-year, but the gross sales difference improved year-on-year [1]. Group 3: Product Development and Market Performance - The company launched the upgraded Collagen Stick 2.0 under its main brand, which focuses on basal membrane barrier repair and achieved top sales during the 618 shopping festival [3]. - The company is focusing on new product launches, including the Rejuvenation Series and the Star Cream, which continue to perform well in the market [3]. - The DTC online direct sales channel and e-commerce platform sales saw significant growth, with revenue of 18.16 billion RMB and 3.91 billion RMB respectively, reflecting year-on-year increases of 13% and 134% [2].

Core Insights - The company reported a robust growth in revenue and profit for the first half of 2025, with a revenue of 3.113 billion yuan, representing a year-on-year increase of 22.5%, and a net profit attributable to the parent company of 1.182 billion yuan, up 20.2% year-on-year [1][2] - The company's gross margin for the first half of 2025 was 81.68%, a decrease of 0.72 percentage points, while the net profit margin was 37.99%, down 0.61 percentage points [1] - The company is a leader in collagen protein skincare products in China, focusing on R&D and expanding into eight consumer brands [2] Financial Performance - In the first half of 2025, the company's sales expense ratio improved by 1 percentage point to 34.01%, while the management expense ratio increased slightly by 0.07 percentage points to 2.65% [1] - The adjusted net profit for the first half of 2025 was 1.205 billion yuan, reflecting a year-on-year growth of 17.4% [1] Product and Brand Development - The company's flagship product line, "Kefumei," achieved a revenue of 2.54 billion yuan in the first half of 2025, marking a 22.7% increase year-on-year [1] - The company launched the "Zhenyu Mixin" series in 2025, focusing on post-surgical skin repair, which aligns well with its medical beauty channel strategy [1] - The "Keli Jin" brand generated a revenue of 500 million yuan in the first half of 2025, with a year-on-year growth of 26.9% [1] Sales Channels and Market Expansion - The direct sales channel generated 2.325 billion yuan in revenue, accounting for 74.7% of total revenue, with the DTC channel contributing 1.816 billion yuan [2] - The company has expanded its offline presence to approximately 1,700 public hospitals, 3,000 private hospitals and clinics, over 130,000 pharmacy stores, and around 6,000 CS/KA stores, including 24 specialty stores in key domestic cities [2] - The company has begun to penetrate the Southeast Asian market by entering Watsons in Malaysia [2] Investment Outlook - The company is expected to achieve net profits attributable to the parent company of 2.505 billion yuan, 3.102 billion yuan, and 3.732 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 21, 17, and 14 times [2]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 82.50 [1]. Core Insights - The company demonstrated rapid growth in H1 2025, achieving revenue of RMB 3.113 billion, a year-on-year increase of 22.5%, and a net profit of RMB 1.18 billion, up 20.6% year-on-year, with a net profit margin of 37.98% [5]. - The company is focusing on long-term strategies, maintaining stable business operations, and ensuring both revenue and profit growth while keeping profitability relatively stable [5]. - The company is expanding the application boundaries of recombinant collagen through research and development, enhancing brand value, and iterating quality products to create a long-term growth matrix [5][6]. Financial Performance - For H1 2025, the company's revenue from its main brand, Kefu Mei, was RMB 2.542 billion, a year-on-year increase of 22.7% [6]. - The company reported a gross margin of 81.68%, with a sales and distribution expense ratio of 34.01%, reflecting optimization in sales expenses [8]. - The company expects to maintain its profit forecast, projecting net profits of RMB 2.6 billion, RMB 3.203 billion, and RMB 3.812 billion for 2025, 2026, and 2027 respectively, with corresponding EPS of RMB 2.53, RMB 3.11, and RMB 3.71 [9]. Market Position and Growth Potential - The company has successfully expanded its offline channels, entering approximately 1,700 public/private hospitals and clinics, and over 13,000 chain pharmacies [7]. - The direct sales through e-commerce platforms showed significant growth, achieving revenue of RMB 391 million, a year-on-year increase of 133.6% [7]. - The company is also exploring international markets, having entered Watsons in Malaysia, which is expected to provide new growth opportunities [7]. Valuation Metrics - The company is valued at a market capitalization of HKD 55.955 billion, with a closing price of HKD 52.25 as of August 28 [1]. - The projected PE ratios for the upcoming years are 24.23 for 2025, 19.22 for 2026, and 15.60 for 2027, indicating a favorable valuation compared to peers [4][11].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 56.57 CNY [4][10]. Core Insights - The company focuses on big product lines and streamlining its main brand SKU strategy to drive continuous improvement in gross margin. However, the significant decline in offline channels in 1H25 has impacted main brand growth. There are expectations for new products to expand the consumer base and improve operational efficiency on platforms like Douyin [2][10]. - In 1H25, the company reported total revenue of 2.372 billion CNY, a year-on-year decline of 15.43%, and a net profit attributable to the parent company of 247 million CNY, down 49.0% year-on-year. The gross margin improved to 76.0%, up 3.42 percentage points, attributed to a focus on big products and reduced promotions [10][11]. - The company has adjusted its EPS forecasts for 2025 and 2026 to 1.12 CNY and 1.49 CNY, respectively, reflecting the impact of short-term offline channel adjustments and product line streamlining [10][11]. Financial Summary - For 2023A, the total revenue is projected at 5.522 billion CNY, with a year-on-year growth of 10.1%. The net profit attributable to the parent company is expected to be 757 million CNY, down 28.0% [3][11]. - The company’s gross margin is expected to improve to 75.3% in 2025E, with a net profit margin of 8.6% [11]. - The company’s total assets are projected to reach 8.456 billion CNY by 2025E, with total liabilities of 1.936 billion CNY [11]. Market Performance - The stock has a 52-week price range of 39.34 CNY to 70.30 CNY, with a total market capitalization of 19.871 billion CNY [5][10]. - The stock has shown an absolute increase of 14% over the past 12 months, although it has underperformed relative to the index by 41% [9][10].

Core Viewpoint - UBS has downgraded the net profit forecast for Giant Bio (02367) for 2025 to 2027 by 4-10%, primarily due to a revision in revenue growth expectations for the Comfy business, although this impact is offset by an improvement in sales expense ratio [1] Group 1: Financial Performance - The target price for Giant Bio has been reduced from HKD 93.1 to HKD 79.5 while maintaining a "Buy" rating [1] - The company's revenue showed a robust growth of 23% year-on-year, driven mainly by online sales rather than distributor channels [1] - The net profit margin reached 38%, with the marketing expense ratio decreasing by 1.1 percentage points to 34% year-on-year [1] Group 2: Brand and Market Position - Despite earlier concerns related to allegations of fraud affecting the Comfy brand's collagen bars, it still contributes nearly 30% to brand sales [1] - Management has reiterated ongoing collaborations with top influencers to enhance consumer education and is on track with preparations for the Double 11 shopping festival [1] Group 3: Future Guidance - The company maintains its guidance for a sales growth of 25% to 28% year-on-year and a profit target of RMB 2.5 billion to 2.55 billion for 2025 [1]